Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial
Thuy‐Anh Le, Joshua Chen, Christopher Changchien, Michael R. Peterson, Yuko Kono, Heather Patton, Benjamin L. Cohen, David Brenner, Claude Sirlin, Rohit Loomba, for the San Diego Integrated NAFLD Research Consortium (SINC) – 20 March 2012 – Bile acid sequestrants (BAS) lower plasma low density lipoprotein levels and improve glycemic control. Colestimide, a BAS, has been claimed by computed tomography to reduce liver fat. Therefore, we examined the efficacy of colesevelam, a potent BAS, to decrease liver fat in patients with biopsy‐proven nonalcoholic steatohepatitis (NASH).